←
Susan Bal715 posts
Susan Bal avatar

Susan Bal

@SusanBal9

Plasma Cell Disorders; Tx/Cell Therapy Physician @ UAB Medicine via Memorial Sloan Kettering; U of Cincinnati & Kettering; Tweets=My opinions #mmsm

◷ Joined March 2017▧ 87 Photos and videos
Susan Bal avatar
Susan Bal@SusanBal9·Jan 19

I'm running with MMRF Team for Cures to fundraise for the Multiple Myeloma Research Foundation. With each mile, I hope to accelerate the discovery of cures for the second most common blood cancer. Will you help me reach my fundraising goal? do.nr/swmnku18 via @DonorDrive

Susan Bal avatar
Susan Bal@SusanBal9·17 Mar 2025

Thank you for sharing and thanks to @TheLancetHaem for the opportunity to pen this commentary on an important update of a major practice informing - monumental study

Monumen-TAL progress in the treatment of relapsed multiple myeloma - Ongoing drug development of novel agents and deployment of innovative combinations remains paramount in chasing the elusive cure The Lancet Haematology thelancet.com/journals/lanha… #mmsm

Susan Bal avatar
Susan Bal@SusanBal9·30 Sep 2024

We showed identical MRD responses as Quadruplet+ASCT and were able to spare a quarter of patients the toxicity of ASCT. Important to follow long term outcomes but so far so good! Larger studies Master-2 and MIDAS if further answer this and other important qs. But it can be done!

Post attachmentPost attachmentPost attachmentPost attachment
Susan Bal avatar
Susan Bal@SusanBal9·16 Mar 2024

Excellent thread on cilta-cel, only point I would highlight is if you progress on bridging therapy, your risk of fatal outcome 🔝 and in that situation I would not proceed directly with cilta cel but consider other options to lower disease burden!

#mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (I explained this before) 🧵

Susan Bal avatar
Susan Bal@SusanBal9·14 Dec 2023

When we presented this at EHA, less apparent but important to await data from additional patients and f/u at RP2D

Post attachment

Interesting kinetic profile of GPRC5D CART cells- (n=26) hence preliminary - biphasic ? - higher median at 6 months than ide-cel ( will this persistence translate to longer PFS ) (Sadly all cilta-cel articles are behind a paywall @JanssenUS ) #ASH23

Post attachment